TRIM16 acts as a tumour suppressor by inhibitory effects on cytoplasmic vimentin and nuclear E2F1 in neuroblastoma cells
Open Access
- 23 August 2010
- journal article
- research article
- Published by Springer Nature in Oncogene
- Vol. 29 (46) , 6172-6183
Abstract
The family of tripartite-motif (TRIM) proteins are involved in diverse cellular processes, but are often characterized by critical protein–protein interactions necessary for their function. TRIM16 is induced in different cancer types, when the cancer cell is forced to proceed down a differentiation pathway. We have identified TRIM16 as a DNA-binding protein with histone acetylase activity, which is required for the retinoic acid receptor β2 transcriptional response in retinoid-treated cancer cells. In this study, we show that overexpressed TRIM16 reduced neuroblastoma cell growth, enhanced retinoid-induced differentiation and reduced tumourigenicity in vivo. TRIM16 was only expressed in the differentiated ganglion cell component of primary human neuroblastoma tumour tissues. TRIM16 bound directly to cytoplasmic vimentin and nuclear E2F1 in neuroblastoma cells. TRIM16 reduced cell motility and this required downregulation of vimentin. Retinoid treatment and enforced overexpression caused TRIM16 to translocate to the nucleus, and bind to and downregulate nuclear E2F1, required for cell replication. This study, for the first time, demonstrates that TRIM16 acts as a tumour suppressor, affecting neuritic differentiation, cell migration and replication through interactions with cytoplasmic vimentin and nuclear E2F1 in neuroblastoma cells.Keywords
This publication has 42 references indexed in Scilit:
- The estrogen-responsive B box protein (EBBP) restores retinoid sensitivity in retinoid-resistant cancer cells via effects on histone acetylationCancer Letters, 2009
- Cytoplasmic functions of the tumour suppressor p53Nature, 2009
- Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group StudyJournal of Clinical Oncology, 2009
- Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancerBreast Cancer Research, 2008
- The atRA‐responsive gene neuron navigator 2 functions in neurite outgrowth and axonal elongationDevelopmental Neurobiology, 2008
- Altered Cytoplasmic-to-Nuclear Ratio of Survivin Is a Prognostic Indicator in Breast CancerClinical Cancer Research, 2008
- Regulation of the transition from vimentin to neurofilaments during neuronal differentiationCell Motility, 2003
- CURRENT PRACTICE IN PEDIATRIC PATHOLOGY: Peripheral Neuroblastic Tumors: Pathologic Classification Based on Recommendations of International Neuroblastoma Pathology Committee (Modification of Shimada Classification)Pediatric and Developmental Pathology, 2000
- Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic AcidNew England Journal of Medicine, 1999
- Characterisation of a novel cysteine/histidine‐rich metal binding domain from Xenopus nuclear factor XNF7FEBS Letters, 1993